MapLight Therapeutics develops small-molecule CNS drugs, led by ML-007C-MA, an M1/M4 muscarinic agonist co-formulated with a peripheral anticholinergic to limit side effects. It treats schizophrenia (Phase 2 readout 2H26) and Alzheimer's disease psychosis. MapLight synchronizes agonist and antagonist pharmacokinetics to dampen side effects.
acquisitions n=0
No cited completed company acquisition recorded.
traction n=0
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
valuations n=0
No cited valuation with an explicit basis is recorded.
revenue multiples n=0
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.